Which drug hunters are making the greatest scientific contributions to drug discovery R&D? Our non-profit partner, California Life Sciences, is currently taking nominations for scientists or teams for their 2021 Pantheon Awards until July 16th. You should show California drug hunters some love by nominating them here.

You can nominate a person or team (Dan Erlanson or the sotorasib KRAS(G12C) team for example), but you can’t nominate an entire company (Amgen). The Scientific Advancement Award is new, but past winners in the Life Sciences Leadership category have included UC Berkeley’s Jennifer Doudna, Vir’s George Scangos, and Gilead’s John Martin.

Here’s some industry drug hunters we have in mind for this award. We’d love to hear what you think!

Sotorasib (AMG-510) structure (Amgen's KRAS(G12C) inhibitor)
Sotorasib (AMG-510) was the first KRAS(G12C) inhibitor to receive FDA approval this year.

View full award details and eligibility criteria here

California has been the leading state in R&D of cutting-edge treatments for decades, and a lot of it is because of the diversity and concentration of talented scientists here. Combination immunotherapy, synthetic lethality, bi-specifics, oligonucleotide and RNA therapies, as well as gene and cell therapies are just some of the cutting-edge areas that California’s top scientists have been pioneering. No matter who gets put forward, it’s likely to be an interesting pool of candidates to vote on later this year.

Explore drughunter.com for more on drug discovery.